MedElevator Войти в исследования
← Поиск публикаций

DOI 10.26599/1671-5411.2023.04.001

Медицинская библиотека · Journal of geriatric cardiology : JGC · 2023

Evaluation of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: a prospective multicenter single-arm interventional study.

Yin Xiao-Yun, Zhang Yun-Mei, Shen Ai-Dong, Wang Jing-Ping, Lian Zhe-Xun, Shao Yi-Bing, Zhang Wen-Qi, Zhang Shu-Ying, Zheng Yang, Cheng Kang, Xu Biao, Shen Cheng-Xing, Huang Rong-Chong, Guo Jin-Cheng, Fu Guo-Sheng, Shan Dong-Kai, Li Dan-Dan, Chen Yun-Dai

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the feasibility and tolerability of metoprolol standard dosing pathway (MSDP) in Chinese patients with acute coronary syndrome (ACS).

METHODS

In this multicenter, prospective, open label, single-arm and interventional study that was conducted from February 2018 to April 2019 in fifteen Chinese hospitals. A total of 998 hospitalized patients aged ≥ 18 years and diagnosed with ACS were included. The MSDP was applied to all eligible ACS patients based on the standard treatment recommended by international guidelines. The primary endpoint was the percentage of patients achieving the target dose at discharge (V2). The secondary endpoints included the heart rate and blood pressure at V2 and four weeks after discharge (V4), and percentage of patients experiencing bradycardia (heart rate < 50 beats/min), hypotension (blood pressure < 90/60 mmHg) and transient cardiac dysfunction at V2 and V4.

RESULTS

Of the 998 patients, 29.46% of patients achieved the target dose (≥ 95 mg/d) at V2. The total population was divided into two groups: target group (patients achieving the target dose at V2) and non-target group (patients not achieving the target dose at V2). There was significant difference in the reduction of heart rate from baseline to discharge in the two groups (-4.97 ± 11.90 beats/min vs. -2.70 ± 9.47 beats/min, P = 0.034). There was no significant difference in the proportion of bradycardia that occurred in the two groups at V2 (0 vs. 0, P = 1.000) and V4 (0.81% vs. 0.33%, P = 0.715). There was no significant difference in the proportion of hypotension between the two groups at V2 (0.004% vs. 0.004%, P = 1.000) and V4 (0 vs. 0.005%, P = 0.560). No transient cardiac dysfunction occurred in two groups during the study. A total of five adverse events (1.70%) and one serious adverse event (0.34%) were related to the pathway in target group.

CONCLUSIONS

In Chinese ACS patients, the feasibility and tolerability of the MSDP have been proved to be acceptable.

Для цитирования: Yin Xiao-Yun, Zhang Yun-Mei, Shen Ai-Dong, Wang Jing-Ping, Lian Zhe-Xun, Shao Yi-Bing, Zhang Wen-Qi, Zhang Shu-Ying, Zheng Yang, Cheng Kang, Xu Biao, Shen Cheng-Xing, Huang Rong-Chong, Guo Jin-Cheng, Fu Guo-Sheng, Shan Dong-Kai, Li Dan-Dan, Chen Yun-Dai. Evaluation of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: a prospective multicenter single-arm interventional study.. Journal of geriatric cardiology : JGC. 2023. DOI: 10.26599/1671-5411.2023.04.001.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.